

## Olaparib in gBRCA Mutated Pancreatic Cancer Whose Disease Has Not Progressed on First Line Platinum-Based Chemotherapy (POLO)

This study is currently recruiting participants. (see [Contacts and Locations](#))

Verified September 2015 by AstraZeneca

**Sponsor:**

AstraZeneca

**Collaborator:**

Myriad Genetics – BRCA analysis test for FDA Premarket Approval (PMA)

**Information provided by (Responsible Party):**

AstraZeneca

ClinicalTrials.gov Identifier:

NCT02184195

First received: June 6, 2014

Last updated: September 16, 2015

Last verified: September 2015

[History of Changes](#)

[Full Text View](#)

[Tabular View](#)

[No Study Results Posted](#)

[Disclaimer](#)

[How to Read a Study Record](#)

### Purpose

A **Phase III**, Randomised, Double Blind, Placebo Controlled, Multicentre Study of Maintenance **Olaparib** Monotherapy in Patients with gBRCA Mutated Metastatic Pancreatic Cancer whose Disease Has Not Progressed on First Line Platinum Based Chemotherapy

Condition	Intervention	Phase
Germline BRCA1/2 Mutations and Metastatic Adenocarcinoma of the Pancreas	Drug: <b>Olaparib</b> Drug: Placebo	<b>Phase 3</b>

Study Type: Interventional

Study Design: Allocation: Randomized

Endpoint Classification: Efficacy Study

Intervention Model: Parallel Assignment

Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)

Primary Purpose: Treatment

Official Title: A **Phase III**, Randomised, Double Blind, Placebo Controlled, Multicentre Study of Maintenance **Olaparib** Monotherapy in Patients With gBRCA Mutated Metastatic Pancreatic Cancer Whose Disease Has Not Progressed on First Line Platinum Based Chemotherapy

**Resource links provided by NLM:**

[MedlinePlus](#) related topics: [Cancer](#) [Pancreatic Cancer](#)

[Drug Information](#) available for: [Olaparib](#)

[Genetic and Rare Diseases Information Center](#) resources: [Pancreatic Cancer](#)

[U.S. FDA Resources](#)

**Further study details as provided by AstraZeneca:**

Primary Outcome Measures:

- Progression free survival (PFS) by central review of modified RECIST 1.1 [ Time Frame: Up to 4 years ] [ Designated as safety issue: No ]  
Efficacy by assessment of PFS (time from randomisation to objective disease progression according to modified Response Evaluation Criteria in Solid Tumours (RECIST 1.1) or death) of olaparib maintenance monotherapy compared to placebo, using blinded independent central review (BICR) of radiological scans.

Secondary Outcome Measures:

- Overall survival (OS) [ Time Frame: Up to 4 years ] [ Designated as safety issue: No ]  
Efficacy by assessment of OS (time from randomisation to death by any cause) of olaparib maintenance monotherapy compared to placebo
- Time from randomisation to second progression or death (PFS2) [ Time Frame: Up to 4 years ] [ Designated as safety issue: No ]  
Efficacy by assessment of PFS2 (time from randomisation to second progression, defined as objective radiological or symptomatic progression, or death) of olaparib maintenance monotherapy compared to placebo.

- Time from randomisation to first subsequent therapy or death (TFST) [ Time Frame: Up to 4 years ] [ Designated as safety issue: No ]  
Efficacy by assessment of TFST (time from randomisation to the earlier of first subsequent therapy following study treatment discontinuation, or death) of olaparib maintenance monotherapy compared to placebo.
- Time from randomisation to second subsequent therapy or death (TSST) [ Time Frame: Up to 4 years ] [ Designated as safety issue: No ]  
Efficacy by assessment of TSST (time from randomisation to the earlier of second subsequent therapy following study treatment discontinuation, or death) of olaparib maintenance monotherapy compared to placebo.
- Time from randomisation to study treatment discontinuation or death (TDT) [ Time Frame: Up to 4 years ] [ Designated as safety issue: No ]  
Efficacy by assessment of TDT (time from randomisation to the earlier of study treatment discontinuation or death) of olaparib maintenance monotherapy compared to placebo. compared to placebo.
- Objective response rate by BICR using modified RECIST 1.1 [ Time Frame: Up to 4 years. ] [ Designated as safety issue: No ]  
Efficacy by assessment of objective response rate according to modified RECIST 1.1 of olaparib maintenance monotherapy compared to placebo
- Disease control rate by BICR using modified RECIST 1.1 [ Time Frame: Up to 4 years ] [ Designated as safety issue: No ]  
Efficacy by assessment of disease control rate according to modified RECIST 1.1 of olaparib maintenance monotherapy compared to placebo.
- Adjusted mean change from baseline in global quality of life (QoL) score from the EORTC-QLQ-C30 questionnaire [ Time Frame: Up to 4 years ] [ Designated as safety issue: No ]  
Assessment of the effect of olaparib on health-related quality of life (QoL) as measured by the EORTC-QLQ-C30 global QoL scale
- Safety and tolerability of **olaparib** [ Time Frame: Up to 4 years ] [ Designated as safety issue: Yes ]  
Assessment of adverse events (AEs), physical examination, vital signs including blood pressure (BP), pulse, electrocardiogram (ECG) and laboratory findings including clinical chemistry and haematology.
- Improvement rate of global quality of life (QoL) [ Time Frame: Up to 4 years ] [ Designated as safety issue: No ]  
Assessment of the effect of olaparib on improvement rate of global health status/QoL and pancreatic pain as measured by the EORTC-QLQ-C30 global QoL scale and the PAN-26 pancreatic pain scale.

Estimated Enrollment: 145  
 Study Start Date: December 2014  
 Estimated Study Completion Date: July 2016  
 Estimated Primary Completion Date: May 2016 (Final data collection date for primary outcome measure)

<u>Arms</u>	<u>Assigned Interventions</u>
Experimental: <b>Olaparib</b> <b>Olaparib</b> tablets po. 300 mg twice daily	Drug: <b>Olaparib</b> Tablet -100mg Drug: <b>Olaparib</b> Tablet-150mg
Placebo Comparator: Placebo Placebo tablets twice daily	Drug: Placebo Match <b>Olaparib</b> 100mg placebo Drug: Placebo Match <b>Olaparib</b> 150mg placebo

**Detailed Description:**

Approximately 145 patients will be randomised using an Interactive Voice Response System /Interactive Web Response System (IVR/IWR system) in a 3:2 ratio (Olaparib:placebo) to the treatments as specified below :

- Olaparib tablets p.o. 300 mg twice daily
- Matching placebo tablets p.o. twice daily Eligible patients will be those patients with pancreas cancer previously treated for metastatic disease who have not progressed following completion of at least 16 weeks (can be more) of first line platinum-based chemotherapy. All patients must have a known deleterious or suspected deleterious germline BRCA mutation to be randomised; this may have been determined prior to enrolment into the study or may be assessed as part of the enrolment procedure for the study (via centrally provided MyriadIntegrated BRAC.

Patients will be randomised within 6 weeks after their last dose of chemotherapy (last dose is the day of the last infusion) and treatment started as soon as possible but no less than 4 and no more than 8 weeks of the last chemotherapy dose. At the time of starting protocol treatment, all previous chemotherapy treatment should be discontinued.

Following randomisation, patients will attend clinic visits weekly for the first 4 weeks of treatment (Days 8, 15, 22 and 29). Patients will then attend clinic visits every 4 weeks whilst on study treatment. Patients should continue to receive study treatment until objective radiological disease progression as per RECIST as assessed by the investigator and as long as in the investigator's opinion they are benefiting from treatment and they do not meet any other discontinuation criteria.

Once a patient has progressed the patient will be followed for second progression (PFS2) every 8 weeks and then survival until the final analysis.

 **Eligibility**

Ages Eligible for Study: 18 Years and older  
Genders Eligible for Study: Both  
Accepts Healthy Volunteers: No

#### Criteria

##### Key Inclusion Criteria

- Histologically or cytologically confirmed pancreas adenocarcinoma receiving initial chemotherapy for metastatic disease and without evidence of disease progression on treatment
- Patients with measurable disease and/or non-measurable or no evidence of disease assessed at baseline by CT (or MRI where CT is contraindicated) will be entered in this study.
- Documented mutation in gBRCA1 or gBRCA2 that is predicted to be deleterious or suspected deleterious
- Patients are on treatment with a first line platinum-based (cisplatin, carboplatin or oxaliplatin) regimen for metastatic pancreas cancer, have received a minimum of 16 weeks of continuous platinum treatment and have no evidence of progression based on investigator's opinion.
- Patients who have received platinum as potentially curative treatment for a prior cancer (eg ovarian cancer) or as adjuvant/neoadjuvant treatment for pancreas cancer are eligible provided at least 12 months have elapsed between the last dose of platinum-based treatment and initiation of the platinum-based chemotherapy for metastatic pancreas cancer.

##### Major Exclusion Criteria:

- gBRCA1 and/or gBRCA2 mutations that are considered to be non detrimental (eg, "Variants of uncertain clinical significance" or "Variant of unknown significance" or "Variant, favour polymorphism" or "benign polymorphism" etc.)
- Progression of tumour between start of first line platinum based chemotherapy for metastatic pancreas cancer and randomisation.
- Cytotoxic chemotherapy or non-hormonal targeted therapy within 28 days of Cycle 1 Day 1 is not permitted.
- Exposure to an investigational product within 30 days or 5 half lives (whichever is longer) prior to randomisation
- Any previous treatment with a PARP inhibitor, including Olaparib

#### ▶ Contacts and Locations

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see [Learn About Clinical Studies](#).

Please refer to this study by its ClinicalTrials.gov identifier: NCT02184195

#### Contacts

Contact: AstraZeneca Clinical Study Information Center 1-877-240-9479 [information.center@astrazeneca.com](mailto:information.center@astrazeneca.com)  
Contact: AstraZeneca Cancer Study Locator Service <http://www.emergingmed.com/networks/AstraZeneca> 001-877-400-4656 [astrazeneca@emergingmed.com](mailto:astrazeneca@emergingmed.com)

 [Show 96 Study Locations](#)

#### Sponsors and Collaborators

AstraZeneca

Myriad Genetics – BRCA analysis test for FDA Premarket Approval (PMA)

#### ▶ More Information

No publications provided

Responsible Party: AstraZeneca  
ClinicalTrials.gov Identifier: [NCT02184195](#) [History of Changes](#)  
Other Study ID Numbers: D081FC00001, 2014-001589-85  
Study First Received: June 6, 2014  
Last Updated: September 16, 2015  
Health Authority: United States: Food and Drug Administration  
Australia: National Health and Medical Research Council  
France: Afssaps - Agence française de sécurité sanitaire des produits de santé (Saint-Denis)  
Germany: Federal Institute for Drugs and Medical Devices  
United Kingdom: Medicines and Healthcare Products Regulatory Agency  
Canada: Canadian Institutes of Health Research  
Israel: Israeli Health Ministry Pharmaceutical Administration  
Spain: Spanish Agency of Medicines  
Belgium: Federal Agency for Medicinal Products and Health Products  
Korea: Food and Drug Administration

Keywords provided by AstraZeneca:

BRCA, metastatic adenocarcinoma pancreas, maintenance **olaparib** monotherapy, first line platinum chemotherapy, pancreatic cancer, PARP inhibitor

Additional relevant MeSH terms:

Adenocarcinoma	Endocrine System Diseases
Pancreatic Neoplasms	Neoplasms
Carcinoma	Neoplasms by Histologic Type

Digestive System Diseases  
Digestive System Neoplasms  
Endocrine Gland Neoplasms

Neoplasms by Site  
Neoplasms, Glandular and Epithelial  
Pancreatic Diseases

ClinicalTrials.gov processed this record on October 08, 2015